Detalhe da pesquisa
1.
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
Mol Cancer Ther
; 22(6): 765-777, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042205
2.
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
J Immunother Cancer
; 11(4)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068796
3.
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
Mol Cancer Ther
; 14(3): 692-703, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25589493